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Huaan chorionic gonadntropin (hCG) is a hor.one primarily 
synthesized~and secreted by trophohlast. It is detectable 
in circulation in measurable amount within 8 to 10 days after 
fertilization of the egg1•2 •. Its level rises sharply in 
•~rly phases of pregnancy, attaining a peale at 8 to 10 weeks 
of pregnancy, at which ti•e approximately 4.6 •r of hCG is 
present per litre of serum3. Besides pregnancy, the hormone 
is also •ade by trophoblast.and non-trophoblast. tumours4•6• 
Antibodies against this hormone have wide utility in 
kits enabling the diagnosis-of pregnancy. Likewise, these 
are also servicable in radioimmunoassay• for quantitative 
estimation of the hormone. Qualitative and quantitative 
tests requiring anti•hCG antibodies are also useful in 
identification of hCG synthesizing tumours, their regression 
or progression during therapy and metastasis'. Anti•hCG 
laaunization has also been conceived as an approach for control 
cf fertilitys. Antibodies against .hCG bring about the termination 
of pregnancy in primates9 , and may eventually also serve for 
aenstrual regulation. 
Por these and other appllcations, antibodies of high 
titre, specificity and reproducible characteristics are often 
required. Antibodies generated in animals by active immunization 
areh-terogenous and variable from animal to animal. Purtheraore. 
antibodies against a ~iven antigen constitute only a saall 
·1· 
fractloa of the, total alobullns, evea in the hypert.munized 
aalaa11, with the re1ult that the i•une sera have bulle of 
extraneous protein• with only a tiny part reactlna lpeclficMlly 
' 
aaalast the chosen antigen. Tbese·problns can be laraaly 
raso1Y•4 by development of clones of hybrid cells producing 
excluslYely antibodies against a alven antigen. We describe 
here tl•e successful develop•ent of a hybridoma · secretina 
anti·hCG antibodies. 
MATERIALS AND MEntODS 
~11!1~1~: Balb/C aale mice from either outbred or inbred 
•tock were used for these .. experiments. 
~~~uents: Powdered RPMI-1640 medium was obtained froa Grand 
I1land Biological Company, .. u.s.A. N·2·hydroxyethyl·piperal1na· 
N•2•ethane 1ulfonic aeld (HEPBS). fetal calf serum (PCS) 
vhero puTchased from Plow .Laboratories, V.K. Dimethyl 
sulfoxide (D1-fSO), hypoxanthine, . thymidine, aminopterin, 
Z·•ercaptoothanol vere obtained from Sigma Chemical Company, 
St. Louis, Mo/ U.S.A. 2, 6, 10, 14 • tetra methylpentadecane 
(Pristane) was obtained from Aldrich Chemical Company, Inc., 
u.s.A. Polyethylene glycol (PEG) lSSO was purchased froll 
Serva, Heidolbera, Genany. Human chorionic gonadotropin 
(hCG; 10 11 800 I.U/ag) was made avattable by Dr. Tsona of the 
Population Council, New York. 
Culture and fusion media: . The coapositlon of the different 
aedia used for the maintonanG~ of the myeloma cell line, 
fu1ion and selection of hyrblds was as follows: 
1) RPMI aediua: RPMI actdium was prepared by 
dissolving ln 1 litre of double distilled water, 10.4 1 
RFMI•1640 powder, 2.0 g NaHC03 and 2.38 g HEPES. 100 I.U. 
penclllin and 100 }II streptomycin per ml of the medlW!a 
were also added. The medium vas filtered through 
M1111pore disc. (0.22 u pore size) and stored at 4°C. 
11) Growth medium: Growth mediua was prepared by 
adding 20t sterll~ heat inactivated PCS to RPMI aedtua 
and stored at 4°C. Preah .glutamine at 20mM/al aediua va• 
added if the medium vas kept for aore than 10 days before use. 
iii) Fusion medium,: It w•s prepared by adding sterile 
· o.s ml of 2•mercaptoethano1 (S x 10-2M) to 500 ml of the 
Growth mediua. 
1!) HT 100 X solution: .130 ag hypoxanthine and 30 •• 
thymidine were dissolved in 100 ml of distilled water. To 
facilitate dissolution it was warmed to 4S·S0°C. It was 
sterilized by passing through Mi11ipore disc (0.45 ~ pore· size) 
and stored at ·20°C in S.O ml aliquots. 
v) HAT 100 X solution..:.. .... To prepare HAT 100 X tolutlon 
130 mg hypoxanthine, 1.76 mg aminopterin and 39 •1 thyaidine 
were dissolved in 100 ml of 10 mM Narnt, filtered through 
Milllpore dis~ (0.45 ~ pore size) and sto~ed at -20°C in 
~-~ () zl aliquots. 
-4· 
Yl) HAT and HT aedlua: .HAT or HT aedlua was prepared 
by addlna 1 al of HAT or HT 100 X solutions to tt al of the 
Pusion aedlum. 
Yli) Polyethyl•ne Glycol ( (PEG I): 2 1 PEG • 1550 
vas autoclaved ln a glass tube at 15 pound pressure for . 
ao aln. It vas c~oled to about 60°C and 2.2 al lPMI aedlu. 
and 0.6 al DMSO were auded, mixed and stored at 4°C. 
Yili) Polyethylene Glycol XI (PEG l!l: . 2 1 PBG•l$50 
vas a~toclavvd in a glass .t~be at 15 pound ~ressure for 
20 aln. 6.0 al of RPMI aediua was addod to the cooled PEG, 
the Jolutlon aixed by vortexlng and stored at 4°C. 
~eloaa C6ll line and its malntepanee: . PS·NSI/l•AI 4•1 (NSI) 
a non-secreting variant of P3·N63·Ag a (a cell line of Balb/C 
origin derived from MOPC-21) and which synthesizes only kappa 
Chain vas used in those experiments. This was obtained froa 
Dr. s.x. Kar, ILRAD, Nairobi, lenya. The cell line vas 
cultured in the Growth medium. .To ensure that cells we~e 
as healthy as possible for .fusion, they were kept in losarlthalc 
arovth phase for at least 4 days prior to fusion by subculturlne 
~aa dally. 
Imaunlxatlon of alee: Balb/C male alee. 1Q•12 weeks old were 
iaaunlsed with hCG aceordlns to the .schedule I •· II as shown 
1n Pia.l. 
~eparatlon of spleen cells~ Iaaunlzed alee havint the highest 
tltres of adtl·hCG antibodies in sera were killed by ether 
ane•thesia. Spleen was reaovcd aseeptlcally, placed in 5 al 
of the Growth aediua and cell suspension was aade by teaslng 
the·spleen with a pair of curved forceps. Cluaps and •eabrane 
fragaents were allowed to eettle and the resulting single cell• 
were washed twice with RPMI medium by centrifugation at 100 rpa 
for 5 min. Cells were ~esuipended in RPMI medium, an aliquot 
diluted wlth eqnal volume of Trypan blue (O.lt), eounted in 
heaoeytometer and cell ~onc:entration wai adjusted· to 1 x to1 
cells/at medium. 
Preparation of macrophage feedor cells 
To prepa'l"e feeder cells, _Balb/C llale alee were killed 
by ether anaesthesia, drenched ln 70t alcohol and perltoneua 
exposed. S ml of the cold RPM! m~dium was injedBd into the 
peritoneal cavity with the help of 18G needle, peritoneu• 
tapped with fingers for 1 to 2 aln and cells removed vitb6e 
same needle. Washes from 2 to 4 alee weT& pooled, cells 
centrifuged. at 1200 rpm and resuspended in 10 •1 of the 
Growth medium. An aliquot of cells was diluted with an equal 
volume of Trypan blue (O.lt) and total nucleated cells counted 
·5 
in a hemocytometer. Cells were then diluted to 1 x 10 
cells/al and 1 al of cell suspension plated per well in 
either 24 or 96 well plates (Coster, ZOS Broadway Caabridge. 
0 u.s.A.). The feeder cells were incubated at S7 C in a humidified 
)lt11r.o$phere _of St Co2, 95\ air overnitht before u••~ 
Cell fu.lln and selection of hybrids: S x 106 ayeloaa 
Celli ve~ a~e4 With 5 X 107 splenocytes obtained fro.M an 
~ised alee in a 10 ml plastic tube. The fusion was 
pertoraed as per procedure outlined 1n Plg.2. 24 hrs after 
platina tho fuse4 cells, fusion wediUII froa each well vas 
repl11cecl with 1.5 al of the itAT mediua. The HAT aedlUII was 
changed thrice on alternate days. After that, cultures were 
watched for the arovth of .hyrblds and change in the pH of the 
ae41UM. As soon as the growth was visible aaerosc~pically or 
the medium turned acidic, supernatant wnt removed from each 
well vlth separate pipettes ·and analysed for the presence of 
antl·hCG antibodies. The cells from wells which were positive 
for anti·hCG an~!bodios were transferred to 60 x 15 a. tissu• 
culture petri dishes (Paleon, 1950 Williams Drive, u.s.A.) 
for further propagation of the hybrids. A part of the hybrid 
cella were cloned immediately.in order to keep in check the 
ovorgrowth of the non-producers. Hybrid cells were stored 
in liquid nitrogen. 
Cloni~g of liY:brids: Hybrids positive for antibodies were 
cloned by limiting dilution technique. Hybrid cells were 
411uted in the HT medium and cloned in either 96 or 24 wells 
culture plates preincubated overnight with 1 x 105 feeder 
cells so as to get on average of 1 cell or o.s.cell per well. 
Colonies became visible macroscopically by 1 to 10 days after 
platina and supe~atants from well contatftlng apparently • . 
•lnglo colony were tested for antibody activity. 
Preparation of ascites fluid: To obtain large .. ounts of 
aonoclonal antibodies, Balb/C alee were given lp injection of 
, 
0.5 •1 Pristane. One week later, he•lthy hybrid cells 
( 
1 . 
l•Z x 10 ) secreting antibodies were injected lp. When 
hybrids vera grown as ascites (10 to 11 days), alee were 
tl11e4 by ether anesthesia and the ascites fluid was reaoved 
with the help of 18 G needle attached to 10 ml syringe. 
It vas centrifuged at 1500 rpm for 10 ain to ~emove cells. 
the a1cites fluid was heat inactivated (56°C, SO min). 
centrifuged at 1o,noo g for SO ain.and the supernat~t was 
atored at -zooc in o.s ml .aliquots. 
PTeezlng ol myeloma cells and hybrids: A lOt DMSO aolutlon 
lD the Growth medium was freshly prepared and cooled ln lee. 
Celli to be frozen were centrifuged .and resuspended at a 
concentratlcn of 1.0 • 2.0 x 106 eells/ml 1~ freezing aediua. 
1 to 1.5 al of the cell suspension was distributed in 2 al 
free&ing vials (Wheaton Laboratory Products, Milville, U.S.A.) 
and the vials closed tightly. The freezing vials were 
kept at ·70°C overnight in a well insulated plastic beaker 
with cotton gauze to allow slow cooling. Next day the vials 
were transferred into a liquid nitrogen tank (LR-40, Union 
carbide, 8 Grafton Street, London). 
!Jit$.hodl titre: Anti-hCG antibody titres in the ·sera obtained 
fr~.launlzed alee or in .the supernatants obtained fro• wells 
v1th positive growth of hybrids were determined by radtoimauno• 
JIJay as described elsewhe·relO. 
SP!cificity s~uctles: Us ina the raiolmaunoassay systems, 
the bindinJ of ~h• antl·hCG antlbodiea secreted by hyb.rld 
cells vas dete~ined with 12St-hLH (WHO - Quality control 
a.aaent, Batch No.8010) and 125I-hPSH (WHO - Quality control 
a.aaeat, Batch No.8010). 
USULTS 
Pour fusloa experiment~ ~· .. carried out. In three of 
thea, alee were iattnised.accorcling to Schedule I (Pig.l) 
·each •ouse at the tia~ of.~he experiment had fairly gnod 
ant1·hCG titres in the serua .(Table I). The spleen cella 
· obtain eel from these alee, .however, generated hybt"lds which 
arew in HAT aedium but none .of the well had appreciable titre 
of antl•hCG antibodies (Plg.3, Schedule I). An alternate 
laauni&ation protocol was followed (Schedule II, flg.l). 
Spleen cells fr011 mouse luuni&ed thus, on fusion with NSI 
a;eloaa cells gave rise to 42 wells out of 48 plated, in 
which srowth vas detectable . in the HAT medium. The supematats 
froa 10 of the ve~ls had anti•hCG titre above lOt (Schedule II, 
PiJ.3). 
In the next step, cells ·qf well No.lS with the highest 
antibody titres as well as hybrid cells from wells No.5,16 
an~ 42 were cloned by limiting dilution technique in 96 and 
24 well plates. Hyrbid cells froa other wells as well as 
' 
thete 4 wells weee frozen in liquid nitrogen as stock. 
After cloning. growth of the hybrids vas seen to variable 
extent in each ease (Table 2). Hawever, the anti·hCG antibodies 
' 
were measurable only in n15 clones; 110 out of 112 wells in 
which the hybrids grew were positive for anti•hCG antibodies. 
40 of the8e were taken for further studies. All of them 
made antibodies with high hCG binding capacity ranging frog 
· IS to 9St. The stoek cultures of these 40 clones were frozen. 
s,ecificity studies were "carried out on cloned cells 
froa 10 wells. The reactivity of the antibodies from these 
clones ~ith radiolabelled hCG and.the pituitary gonadotropins 
is given in Table 3. All of thea had high percentage 
noraalized binding with l1CG ranging from 88 to 99.9t. The 
cross-reactivity of the supernatants from 8 wells with hLH 
was less than 4.St. Two wells, however, had antibodies vlth 
higher binding with hUt i.e. well No.84 had 14.1t and well 
No.Sl had ll.St. · As hCG shares a common L-subunit with hPSH 
also, the cross-reactivity of the antibodies with this hroaone 
was also tested. This was, however, negligible. 
Cella fram one of tho wells (P111wao) were injected ip •. 
lnto a Balb/C mouse as per the procedure in the methods. Ascites 
vas developed and on day seventeen the intraperitoneal fluid 
va• aspirated. A single mouse .yielded 4.5 ml of the supernatant 
with a protoin content of 39.7 mg/al. The antl·hCG tltres 
v•re hiah, a binding of sot of 125I·hCG was obtained with 
thiJ superaatant at 4 x 106 dilution. Th•se aro far beyond 
the t1t"s ever seen or reported iD anbaals even when 
hyperilaaunised. 
D!SotJSSJOH 
The technique initially 4eveloped by lbhler and Mi1stetl1•12 
·to obtain hybrid cells by.fusion of a cell making a defined 
type cf antibody with a myeloma cell eapable of continuous 
aultipllcatlon in a culture medium has op'ned out new avenues 
for preparation of highly specific antibodies against different 
typos of antigens. Using.thls technique we have developed a 
number of clones committed to synthesis of anti·hCG antibodies. 
Only a small number of these have been characterised so far. 
Amongst the ten investigated, at least five subsets are detectable. 
One of them is highly specific for ~ding to hCG with nealitible 
binding (belov detectable limit) with h!Jf and hPSH. The 
second subset has high binding with hCG, devo~d of binding 
with PSH and has low, below 21 binding with hUt. The third 
subset had Z.l, binding with hPSH, 0.3t blndina with 
hUI as cosapared to 92.4t bindina with hCG. The fou~h subset 
ha4 a slightly higher but still low •·I· S.lt binding to hLH. 
~d no reactivity with hPSH. The fifth subset ha4 11 to 14t 
;ftac~~Y!ty with hUI. It ls .obvious that antibodies froa 
-11-
these clones react with different portions and conformations 
of hCG. The subset with more appreciable cross-reaction 
with h~ ~ill be binding to conformation shared by the two 
aonadotropins. The existence of clones highly specific: to 
hCG and practically devoid of reactivity with hLH and hPSH 
points to the presence in hCG of conformations unique to it. 
Bach one of these clones .is able to propogate not only in 
culture but importantly a large am~unt of antibody with very 
• 
high titres can be obtained by injecting.these cells into 
the mouse peritoneum. The product of a given clone would be 
of defined specificity and of,consistant characteristics. 
The antibodies from the P.resently described clones can 
have immediate utility as .. standard reagents for radioimmuno• 
assays for hCG. Prelimin~ry experiments have also indicated 
the ability of the antibodies from these clones to neutralize 
the biological activity of hCG in the mouse Leydig cells 
assay. Investigations are in progress to determine whe,her 
these antibodies alone or in mixture would retain potent 
neutralizing capability .!!!.. vivo. In case, they are effective 
fot'· termination of. pregnancy, these can constitute readily 
producible material of standard quality for passive 
bununiz at ion procedures. . . 
·12· 
A,nURber of clones of hybrid cells have been developed 
by fusion of PS-NSI/l•Ag4·1 (NSI) .yeloma cells vlth 
•plonocytea of mice immunize~ vlth hCG. The bindinJ 
characteriatlca of the products of ten clones vit~ ~h• 
three gonadotro;ins e.g. hCG •. hLH ftnd hPSH have been . . 
deterainod. Three clones aake antibodies of high reaetiv1 ty 
. ' " 
with hCG but nogligible binding (below dete~table lialt of 
•••ay) with hPSH ond hLH. The clones when injected in mous• 
peritoneum produce homogenous antibody of very high titre wtth 
consistent characteristics. One of their imminent 
applications is foreseen as standard reagents fur estlllatlon 
of hCG. 
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LBG~NDS TO PIGURB 
Pl1. 1. A sch .. atlc repre~entatloa of the t.aualaatloa 
• ol Balb/C alee with hCG •. 
CPA Coaplete Freund's ·Adjuvant 




Pla. 2. Procedure followed fo~ fusloa of NS~ 111e1ea 
cells with splono¢11es obtalaed froa aou.e immuoiae4 
with hCG. 
Pta. s. SO pl of culture fluid froa each of the 48 we111 la 
which the fused cells ··~· plated, ... teate& for 
its ability to r>ind hCG. _ Porcentage norulizecl 
bindlnJ ~f 1251-hCG ls calculated by the followina 
fo1"11U1atlon. 
Percentage Normalized Binding • ~ : J X 100 
X • Amount of lZSI·hCG boU1ld with test saaple. 
Y • Aaount of 1251-hCG bound in pretence of exc••• 
of etandard anti·hCG antibodlet. · 
1 • Aaount of 12SI·hCG bound in pretence of so ~~ of· 
noraal culture ae41ua. 
Schedulo I 
• ADtl•hCG Titre ln immunl1ed . 14.- 144. 114 
alee f~I'WI 
Prequ.ncy of hybrids positive 





Tltres ln 3 different mice used as donors of splenocyt••· 
•• • Wells positive for anti·hCG antibodies 
We11s wlih growth ol hyr&la ee11s X tOO 
TABLa 2 • CLONING OP ANTI•HCG POSITIVI WELLS 
------------------------------------------WAJ11 No. &to. of wells with . 
arowth/TotQl No. 













TABLE S ·• BINDING awtACTERISTICS OP nm PRODUCTS OP CBLLS 
PION lo I!LLS CLONED PROM R1s 
DtL HUMIIR 
'11 •s 
. P11 WlS 
'xxr•• 
'z:rt"'' 




'til •• 4 
"'111 •s1 
·-·-.. ·~.~ .... ·~ .. -·' ~ 
PERCENTAGE NORMALIZED BIMDIMI 
lZSIODINATED PBPTIDBS 
····················--·····--·-····-··-···· 
hCG hUf hPSH 
Jt.t -
. t2.4 o.s Z~l 
. 14.4 . s.s • 
. 12 .. 6 1.6 • 
.. , .. 
es.a o.a • 
' ,, .. - • ... 
. 15.7 z.o • 
. 88.0 1.4 • 
~ .... 14.1 • 
. t4.S1 11.5 -
IMMUNIZATION SCHEDULES OF MICE 
hCG ~ CFA 
/51JQ. sc 
~ 
! 3 Weeks 
Booster c IF A 
5 !J9. i.p 
! 2 Weeks 
Booster c IF A 
51Jg. i p 
6Weeks 
Schedule I Schedule II 
Oay-4 Day-4 
1J 
hCG in Saline hCG in Saline 
5-10 IJQ. ;, v 200 IJQ. i. p. 
~ Oay-3 ! Day-3 
5-10 IJQ. i V 400 fJQ, i.V.; i.p. 
! Oay-2 ! Day-2 
Ni I 400 IJQ. i v.;i.p. 
! Oay-1 ! Day-1 









NSI ........... r 5x107Spleen cells 
l:x 
~ntnfuge 800 RPM for 5' 
Add Q.Sml PEG-I ! wash c RPMix2 
(41.6%)~ ~ 
t:=---Pellet 
Add Q. 5 ml PEG-II 1 Mix, shake for 60 .. 
(25%)\ 
~x.Rock for 2-3'. 
J 
Add 4 ml RPMI dropwise Z! 
Intermitant Rocking over 
4-s:centrifuge ,800 RPM 
for 10 
Preincubated ~
2 4 hrs c 105 C/: Pellet 









Incubate 37°C in humid chamber gassed 
c 5% C02 
~3BII'fnN 113M 
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